Among these checkpoint molecules, targeting Tim-3/Gal-9 could be a promising therapeutic approach as this has been proposed to specifically promote LSC self-renewal [32,90] and to be upregulated in therapy failure in AML [91]. The gene discussed is HAVCR2; the disease is acute myeloid leukemia.